查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1392087

患者来源的异种移植模型市场：按模型类型、按植入方法、按肿瘤类型、按应用、按最终用户、按地区

Patient Derived Xenograft Model Market, By Model Type, By Implantation Method, By Tumor Type, By Application, By End User, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 140 Pages | 商品交期: 2-3个工作天内

价格
简介目录

患者来源的异质骨移植模型市场规模预计将从 2023 年的 1.054 亿美元增至 2030 年的 3.46 亿美元，预测期内复合年增长率为 18.5%。

报告范围 报告详情
基准年 2022年 2023年市场规模 1.054亿美元
实绩资料 2018-2021 预测期 2023-2030
预测期复合年增长率 18.50% 2030年市场规模预测 3.46亿美元
图 1. 2023 年病患异质骨移植模型的全球市场占有率(%)（按地区）
病人衍生异种移植模型市场-IMG1

患者来源的异质骨移植（患者来源的异种移植）模型是肿瘤学研究中使用的尖端临床前研究工具。这是一种肿瘤模型，透过将癌症患者的肿瘤组织移植到小鼠或其他免疫力缺乏的动物体内，更真实地再现人类肿瘤的行为。患者来源的异种移植模型在药物研发和药物开发中广受欢迎，因为它们可以模拟患者特异性的肿瘤特征和对治疗的反应。

此理论资讯部落格旨在概述患者来源的异质骨移植模型市场，包括市场动态和关键特征。它将帮助相关人员了解该市场当前和未来的趋势并做出资讯的决策。

市场动态：

患者来源的异质骨移植模型市场预计在未来几年将显着成长。有几个因素正在推动这一市场的扩张。首先，全球癌症发生率不断上升，对有效的治疗方案产生了强烈需求。患者来源的异种移植模型是研究肿瘤生物学、评估药物疗效和确定个体化治疗策略的宝贵工具。

此外，对精准医疗和个体化治疗的日益关注也促进了患者来源的异种移植模型市场的成长。这些模型提供了一个平台，用于测试新的候选药物并评估特定患者群体的潜在反应。此外，製药和生技公司越来越多地采用源自患者的异种移植模型进行临床前研究，也推动了市场的成长。

然而，患者来源的异种移植模型市场也面临一些挑战。主要的阻碍因素之一是创建和维护患者来源的异种移植模型的高成本。这些模型的复杂性，包括遗传异质性以及对专门基础设施和专业知识的需求，增加了整体成本。

也就是说，市场上存在一些对主要企业有吸引力的机会。基因组编辑工具和人源化小鼠模型等技术进步将提高源自患者的异种移植模型的效用和可移植性。此外，製药公司、学术研究机构和受託研究机构之间的合作可能会进一步加速患者来源的异种移植模型的采用和可用性。

本研究的主要特点

这项关于患者衍生异种移植模型市场的研究涵盖了各种重要特征，并提供了对市场格局的全面见解。

  • 市场规模与成长：提供全球患者源性异种异质骨移植模型市场的详细分析，包括市场规模（以百万美元为单位）和2023年至2030年预测期间的复合年增长率（以2022年为基准年） 。
  • 商机：透过发现不同细分市场中的潜在收入机会并提出一系列有吸引力的投资提案，帮助相关人员识别商机。
  • 市场驱动因素、抑制因素和机会：它提供了有关市场驱动因素、市场抑制因素和市场机会的重要见解，并揭示了影响市场成长的因素。它还重点介绍了新产品的发布和核准、市场趋势、区域前景以及主要企业采取的竞争策略。
  • 公司概况：根据公司亮点、产品系列、主要成就、财务实绩和策略等参数对全球患者源性异种移植模型市场的主要企业进行了介绍。本研究涵盖的公司名单包括THE JACKSON LABORATORY、Champions Oncology, Inc、Charles River Laboratories、Crown Bioscience、Hera Biolabs、Horizo​​​​n Discovery Ltd.、Oncodesign、Pharmast Services、上海力德生物科技、Aragen Life Sciences Ltd. 、Creative Animodel 、Urosphere、Applied StemCell、药明康德等。
  • 决策见解 本报告为行销人员和负责人提供了宝贵的资讯，帮助他们就产品发布、产品类型升级、经营团队扩张和行销策略做出明智的决策。
  • 相关人员利益：全球病患异质骨移植模型市场报告针对产业内的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。透过用于市场分析的各种策略矩阵促进决策。

目录

第一章 研究目的与假设

  • 研究目标
  • 假设
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
    • 促进因素
  • 癌症研究的增加
    • 抑制因素
  • 患者来源的异种移植模型的局限性
    • 机会
  • 在免疫治疗测试中的应用
  • 影响分析
  • 主要亮点
  • 监管场景
  • 产品发布/核准
  • PEST分析
  • 波特的分析
  • 併购场景

第 4 章 患者来源的异种移植模型市场 -冠状病毒(COVID-19) 大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第 5 章 2018-2030 年病患来源的异种移植模型市场（依模型类型）

  • 介绍
  • 肿瘤外植体模型
  • 细胞株衍生模型
  • 患者来源的类器官
  • 基因改造模型
  • 其他（原代细胞衍生模型、细胞加工模型等）

第六章 2018-2030 年病患来源的异种移植模型市场（依移植方法）

  • 介绍
  • 皮下植入
  • 整形外科移植
  • 其他的

第 7 章 2018-2030 年病患来源的异种移植模型市场（依肿瘤类型）

  • 介绍
  • 胃肠道肿瘤模型
  • 妇科肿瘤模型
  • 呼吸道肿瘤模型
  • 其他肿瘤模型

第 8 章 2018-2030 年病患衍生异种移植模型市场，依最终使用者划分

  • 介绍
  • 製药和生物技术公司
  • 受託研究机构
  • 学术/研究机构
  • 其他的

第 9 章 2018-2030 年病患来源异种移植模型市场（按地区）

  • 介绍
  • 北美洲
  • 美国
  • 加拿大
  • 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 欧洲其他地区
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 东南亚国协
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第10章竞争形势

  • THE JACKSON LABORATORY
  • Champions Oncology, Inc
  • Charles River Laboratories
  • Crown Bioscience
  • Hera Biolabs
  • Horizon Discovery Group
  • Oncodesign
  • Pharmatest Services
  • Shanghai LIDE Biotech
  • Aragen Life Sciences Ltd.
  • Creative Animodel
  • Urosphere
  • Applied StemCell
  • WuXi AppTec

第11章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI6506

The Patient Derived Xenograft Model Market size is expected to reach US$ 346 million by 2030, from US$ 105.4 million in 2023, at a CAGR of 18.5% during the forecast period.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 105.4 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 18.50% 2030 Value Projection: US$ 346 Mn
Figure 1. Global Patient Derived Xenograft Model Market Share (%), by Region, 2023
Patient Derived Xenograft Model Market - IMG1

Patient Derived Xenograft (PDX) Model is a cutting-edge preclinical research tool used in oncology research. It is a type of tumor model where tumor tissues from cancer patients are implanted into mice or other immunodeficient animals to create a more realistic representation of the tumor's behavior in humans. PDX models have gained significant popularity in drug discovery and development due to their ability to mimic patient-specific tumor characteristics and response to treatments.

This theoretical informative blog aims to provide an overview of the Patient Derived Xenograft Model market, including its market dynamics and key features. It will assist stakeholders in understanding the current and future trends in this market and making informed decisions.

Market Dynamics:

The Patient Derived Xenograft Model market is expected to witness substantial growth in the coming years. Several factors are driving this market expansion. Firstly, the increasing prevalence of cancer globally is creating a strong demand for effective treatment options. PDX models offer a valuable tool for studying tumor biology, evaluating drug efficacy, and identifying personalized treatment strategies.

Moreover, the rising focus on precision medicine and personalized therapies further contributes to the growth of the PDX model market. These models provide a platform for testing novel drug candidates and evaluating their potential response in specific patient cohorts. Additionally, the growing adoption of PDX models by pharmaceutical and biotechnology companies for preclinical testing is boosting market growth.

However, the Patient Derived Xenograft Model market also faces some challenges. One of the key restraints is the high cost associated with creating and maintaining PDX models. The complexity of these models, including genetic heterogeneity and the need for specialized infrastructure and expertise, adds to the overall expenses.

Nevertheless, the market presents several attractive opportunities for key players. Advancements in technology, such as genome editing tools and humanized mouse models, enhance the utility and translatability of PDX models. Moreover, collaborations between pharmaceutical companies, academic research institutions, and contract research organizations are likely to further accelerate the adoption and availability of PDX models.

Key Features of the Study:

This study on the Patient Derived Xenograft Model market encompasses various essential features, providing comprehensive insights into the market landscape:

  • Market Size and Growth: The report offers an in-depth analysis of the global Patient Derived Xenograft Model market, including market size (in US$ Million) and compound annual growth rate (CAGR%) for the forecast period of 2023-2030, with 2022 as the base year.
  • Revenue Opportunities: It elucidates potential revenue opportunities across different market segments and presents attractive investment proposition matrices, aiding stakeholders in identifying lucrative opportunities.
  • Market Drivers, Restraints, and Opportunities: The study provides key insights into market drivers, restraints, and opportunities, shedding light on factors influencing market growth. It also highlights new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
  • Company Profiles: Key players in the global Patient Derived Xenograft Model market are profiled based on parameters such as company highlights, product portfolio, key achievements, financial performance, and strategies. The list of companies covered in this study includes THE JACKSON LABORATORY, Champions Oncology, Inc, Charles River Laboratories, Crown Bioscience, Hera Biolabs, Horizon Discovery Ltd., Oncodesign, Pharmatest Services, Shanghai LIDE Biotech, Aragen Life Sciences Ltd., Creative Animodel, Urosphere, Applied StemCell and WuXi AppTec.
  • Decision-Making Insights: The report equips marketers and management authorities with valuable insights to make informed decisions regarding product launches, type up-gradation, market expansion, and marketing tactics.
  • Stakeholder Benefits: The global Patient Derived Xenograft Model market report caters to various stakeholders in the industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts. It provides ease in decision-making through various strategy matrices utilized in analyzing the market.

Patient Derived Xenograft Model Market Segmentation:

  • By Model Type
    • Tumor explant models
    • Cell line derived models
    • Patient derived organoids
    • Genetically engineered models
    • Others (Primary cell derived models, cell processed models etc.)
  • By Implantation Method
    • Subcutaneous Implantation
    • Orthopedic Implantation
    • Others
  • By Tumor Type
    • Gastrointestinal Tumor Model
    • Gynecological Tumor Model
    • Respiratory Tumor Model
    • Other Tumor Model
  • By End User
    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations
    • Academic & Research Institutions
    • Others
  • By Geography
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Top companies in Patient Derived Xenograft Model Market:
    • THE JACKSON LABORATORY
    • Champions Oncology, Inc
    • Charles River Laboratories
    • Crown Bioscience
    • Hera Biolabs
    • Horizon Discovery Ltd.
    • Oncodesign
    • Pharmatest Services
    • Shanghai LIDE Biotech
    • Aragen Life Sciences Ltd.
    • Creative Animodel
    • Urosphere
    • Applied StemCell
    • WuXi AppTec

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Patient Derived Xenograft Model, By Model Type
    • Market Patient Derived Xenograft Model, By Implantation Method
    • Market Patient Derived Xenograft Model, By Tumor Type
    • Market Patient Derived Xenograft Model, By End User
    • Market Patient Derived Xenograft Model, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Increasing Cancer Research
    • Restraints
  • Limitations of PDX Models
    • Opportunities
  • Applications in Immunotherapy Testing
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Patient Derived Xenograft Model Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Patient Derived Xenograft Model Market , By Model Type, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Tumor explant models
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Cell line derived models
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Patient derived organoids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Genetically engineered models
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Others (Primary cell derived models, cell processed models etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

6. Patient Derived Xenograft Model Market , By Model Type, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Subcutaneous Implantation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Orthopedic Implantation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

7. Patient Derived Xenograft Model Market , By Tumor Type, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018- 2030
  • Gastrointestinal Tumor Model
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Gynecological Tumor Model
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Respiratory Tumor Model
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Other Tumor Model
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)

8. Patient Derived Xenograft Model Market , By End User, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018- 2030
    • Segment Trends
  • Pharmaceutical & Biotechnology Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Contract Research Organizations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Academic & Research Institutions
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)

9. Patient Derived Xenograft Model Market , By Region, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Country, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Country 2019-2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030,(US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • THE JACKSON LABORATORY
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Champions Oncology, Inc
  • Charles River Laboratories
  • Crown Bioscience
  • Hera Biolabs
  • Horizon Discovery Group
  • Oncodesign
  • Pharmatest Services
  • Shanghai LIDE Biotech
  • Aragen Life Sciences Ltd.
  • Creative Animodel
  • Urosphere
  • Applied StemCell
  • WuXi AppTec
  • Analyst Views

11. Section

  • Research Methodology
  • About us